Clinical Trial Search

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 71 Participants

Primary: Dose-limiting Toxicity — 0; 0 Participants

Primary: Muscle Sympathetic Nerve Activity at Rest — 41; 43.8 bursts/minute

Primary: Participants Determined to be True Positives for Pulmonary Arterial Hypertension — 10; 15; 10; 5 Participants

Primary: Airway Submucosal Inflammatory Cells Ratio Change From Baseline to EOT. — 0.11; 0.75; 1.11; 0.81 Ratio — p=<0.001

Primary: Overall Survival — 4.8; 6.4 months

Primary: Part 1, Part 2 (Group 2): Number of Participants With Unsolicited Adverse Events — 33; 10; 32; 3 Participants

Primary: Number of Gadolinium-enhancing T1 Lesions Per MRI Scan - Core Part — 0.0670; 1.0413 lesions per scan — p=<0.001

Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 4; 1; 3…

Primary: MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants — 100.0; 95.3 percentage of participants — p=0.1475

Primary: Efficacy of the RH5.1/AS01 Vaccine by Demonstrating a Reduced PMR in Vaccinated Subjects Compared to Infectivity Controls Against 3D7 Clone Parasites in a CHMI Model…

Primary: Change in Oxygenation Parameter of P(A-a)O2 Gradient by Day 6 — -102.3; -30.5 millimeters of mercury (mmHg)

Primary: Prostate Specific Antigen (PSA) Response Rate — 6 Participants

Primary: Time to First Pulmonary Exacerbation — NA; NA Weeks

Primary: Progression-Free Survival (PFS) in All Randomized Participants and Participants With PTEN Loss Tumors at Primary Analysis — 6.57; 7.52; 7.10; 7.39 months — p== 0.56